Overview
Alpha IRB was acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to expand their IRB capabilities.
Significance
Recent trends in the healthcare industry have significantly impacted the need for Institutional Review Boards (IRBs). The increasing complexity and scale of research studies, coupled with the ethical challenges posed by emerging technologies, have amplified the importance of robust ethical oversight. The proliferation of big data analytics, precision medicine, and genetic research has expanded the scope of healthcare research, necessitating careful IRB review to safeguard participant rights and privacy. The emphasis on patient-centered care and shared decision-making has heightened the need for IRBs to ensure that research aligns with patient preferences and values. Additionally, the globalization of research collaborations and the involvement of vulnerable populations have underscored the crucial role of IRBs in maintaining ethical standards across diverse settings and protecting the rights and well-being of research participants.
Founded in 2007, Alpha IRB is a highly regarded organization with a mission to protect the rights and welfare of human research subjects without compromise while delivering premium customer service. Their white-glove service and integrity are well known in the industry, establishing Alpha IRB as a trusted entity. The organization’s market leadership position and exceptional reputation made it an attractive acquisition for Sabai Global.
Crosstree’s Role
Crosstree’s expertise in the pharma services industry and deep understanding of Alpha IRB’s unique value proposition helped the firm advise Alpha IRB in identifying Sabai Global as the ideal transaction partner through:
- Presenting the client’s unique value proposition to help them achieve the optimal outcome
- Helping client find the right partner to expand their footprint in the US
- Positioning client to maximize value
- Developing and articulating a strong value proposition which connected client capabilities with market trends to weave a compelling narrative for potential buyers
Latest Deals
Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
ClinChoice Acquires CROMSOURCE to Expand CRO Capabilities Globally
anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally
OpenClinica Completes Growth Recapitalization with Thompson Street Capital Partners to Accelerate Enablement of Clinical Trials
